The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

As I filled out a waiver so he could enter the store’s small play area, I noticed I was the only parent present.” ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

“He’s just, as you can see, unstoppable,” said Noah’s dad, Andrew Beighley. “For him to still be that happy is something else,” agreed Noah’s mom, Shanice Beighley. Noah is at risk of having a serious ...

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...